Thrombotic microangiopathy (TMA) is characterized by thrombocytopenia, microangiopathic
haemolytic anaemia and end organ damage. TMAs have varying underlying …

Transplantation-associated thrombotic microangiopathy (TA-TMA) is an increasingly
recognized complication of hematopoietic cell transplantation (HCT) associated with …

Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-
TMA) is a severe and potentially life-threatening complication. HSCT-TMA is often …

Background Transplant‐associated thrombotic microangiopathy (TA‐TMA) is an endothelial
injury complication of hematopoietic stem cell transplant (HSCT) leading to end‐organ …

Transplant-associated thrombotic microangiopathy (TA-TMA) and sickle cell disease (SCD)
share features of endothelial and complement activation. Thus, we hypothesized that SCD is …

Transplant-associated thrombotic microangiopathy (TA-TMA) is an increasingly recognized
complication of allogeneic and autologous hematopoietic cellular therapy (HCT), associated …

The efficacy and outcome of therapeutic plasma exchange (TPE) for transplant-associated
thrombotic microangiopathy (TA-TMA) remain controversial. We therefore sought to evaluate …

Terminal complement blockade by humanised monoclonal antibody eculizumab has been
used to treat transplantation-associated thrombotic microangiopathy (TA-TMA) in recent …

Transplant-associated thrombotic microangiopathy (TA-TMA) is an endothelial injury
syndrome that complicates hematopoietic stem cell transplant (HSCT). Morbidity and …

Novel therapeutic agents for TA-TMA inhibition of the complement system are under
investigation and prophylactic strategies of endothelial protection are emerging. Further …